OC-75: In vivo ANTITUMORAL ACTIVITY OF Thalassia testudinum EXTRACT IN A SYNGENEIC COLON TUMOR MODEL

J Pharm Pharmacogn Res 3(suppl. 1): S87, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-75: In vivo ANTITUMORAL ACTIVITY OF Thalassia testudinum EXTRACT IN A SYNGENEIC COLON TUMOR MODEL

Hernández I1, Vanden Berghe W2, Paz-Lopes M3, Labrada M4, Delgado L1, Op de Beeck K5, Naulaerts S6, Laukens K6, Van Camp G5, Hevia G4, Rodríguez JC7, dos Reis C8, Cassali D8, Fernández MD1, Delgado R9, Rodeiro I1.

1Pharmacology Department, Center of Marine Bioproducts (CEBIMAR), Havana, Cuba. E-mail: ivones@cebimar.cu
2Laboratory of Protein Chemistry, Proteomics and Epigenetic Signaling (PPES), Department of Biomedical Sciences, University of Antwerp (UA), Antwerp, Belgium.
3Laboratory of antitumor substances, Pharmacology Department, Biological Sciences Institute, UFMG, Belo Horizonte, Brazil.
4Center of Molecular Immunology (CIM), Havana, Cuba.
5Laboratory of Cancer Research and Clinical Oncology, Center of Medical Genetics, University of Antwerp, Belgium
6Advanced Database Research and Modelling (ADReM), Biomina, University of Antwerp (UA), Antwerp, Belgium.
7Labotatory of Pathology, Oncology Hospital, Havana, Cuba.
8Laboratory of Comparative Pathology, Pharmacology Department, Biological Sciences Institute, UFMG, Belo Horizonte, Brazil.
9Center for Pharmaceutical Research and Drug Development (CIDEM), Havana, Cuba.

 

Introduction: The diversity of organisms in the marine environment has identified novel marine natural products that could be developed as antitumor compounds. The aqueous ethanol extract from the leaves of marine plant Thalassia testudinum is currently being developed in Cuba as a nutritional supplement due to its promising pharmacological properties. Methods: The present study explored the antitumor activity of T. testudinum extract in a primary colon cancer model. This syngeneic model, ectopic/subcutaneous allograft was performed: with CT26.WT cells. Results: A significant reduction of tumor volume and survival with increasing oral dependent dose of the product was observed. The highest antitumor effects were obtained at 100 mg/kg. Histological and immune-histochemical analysis revealed a protection of progression tumor dose-dependent manner. In addition, T. testudinum extract prevented the tumor-induced oxidative stress in a mice colon cancer model by reducing lipid and protein damage, together with a preservation of antioxidant system. Upon further investigation of up/down regulation oncogenes in response to T. testudinum extract by Illumina bead array and subsequent Ingenuity Pathway Analysis, various molecular and cellular targets were identified related to cancer progression. Conclusions: these results revealed that T. testudinum extract and its phytochemical constituents hold promise for development of new antitumor product.

Citation Format: Hernández I, Vanden Berghe W, Paz-Lopes M, Labrada M, Delgado L, Op de Beeck K, Naulaerts S, Laukens K, Van Camp G, Hevia G, Rodríguez JC, dos Reis C, Cassali D, Fernández MD, Delgado R, Rodeiro I (2015) In vivo antitumoral activity of Thalassia testudinum extract in a syngeneic colon tumor model. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S87. Abstract nr OC-75.